A single treatment with a CRISPR-Cas9 based gene editing therapy is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful ...
Catalyst Biosciences has built a protease medicines platform for engineering protease therapeutics designed to correct disease-causing imbalances in biological cascades. The company currently focuses ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する